DualChip microarray as a new tool in cancer research.
Over the last 5 years, the emergence of gene expression profiling using high-density DNA microarrays led to a better understanding of tumor development and identified new prognostic markers. However, high-density microarrays failed to leap from the researcher's bench to the clinical practice due to their cost, data management and lack of standardization. DualChip low-density DNA microarrays were developed as a new flexible tool that is able to reliably quantify the expression of a limited number of genes of clinical relevance. This review will illustrate how DualChip technology can be applied to tumor diagnosis and tumor-acquired drug resistance.
Gillet
Jean-Pierre
JP
University of Namur, URBC, 61 Rue de Bruxelles, 5000 Namur, Belgium. jpierre.gillet@fundp.ac.be
de Longueville
Françoise
F
Remacle
José
J
D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D004273:DNA, Neoplasm; D019008:Drug Resistance, Neoplasm; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm